A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Inclusion criteria

• ✓. Cabazitaxel is not available
• ✓. The participant's physician deems the participant unsuitable to receive a second taxane regimen due to toxicity risk or prior intolerance Note: a taxane-based regimen consists of at least 2 cycles of a taxane (either as a single agent or in combination with other therapies) administered within the same 2-month period. Participants who cannot continue taxane therapy because of a documented Grade\>=3 taxane related IRR are eligible for enrollment, even if they received fewer than 2 prior cycles of taxane treatment
• ✓. PSMA-targeted lutetium radioligand therapy is unavailable, not accessible, or not clinically indicated.
• ✓. The participant's physician deems the participant unsuitable to receive PSMA-targeted lutetium radioligand therapy.